

Theresa M Harter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5764616/publications.pdf>

Version: 2024-02-01

17
papers

424
citations

759233

12
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

488
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional studies of aldo-keto reductases in <i>Saccharomyces cerevisiae</i> . <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007, 1773, 321-329.	4.1	60
2	Hypotension Due to Kir6.1 Gain-of-Function in Vascular Smooth Muscle. <i>Journal of the American Heart Association</i> , 2013, 2, e000365.	3.7	55
3	Cardiovascular consequences of KATP overactivity in Cantu syndrome. <i>JCI Insight</i> , 2018, 3, .	5.0	44
4	Kinetic Studies of FR-1, a Growth Factor-Inducible Aldo-Keto Reductase. <i>Biochemistry</i> , 1998, 37, 12909-12917.	2.5	43
5	Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by KATP channel overactivity. <i>Journal of Clinical Investigation</i> , 2020, 130, 1116-1121.	8.2	40
6	Functional genomic studies of aldo-keto reductases. <i>Chemico-Biological Interactions</i> , 2001, 130-132, 673-683.	4.0	31
7	ABCC9-related Intellectual disability Myopathy Syndrome is a KATP channelopathy with loss-of-function mutations in ABCC9. <i>Nature Communications</i> , 2019, 10, 4457.	12.8	31
8	Aldo-Keto Reductases in the Eye. <i>Journal of Ophthalmology</i> , 2010, 2010, 1-6.	1.3	22
9	Aldo-keto reductases as modulators of stress response. <i>Chemico-Biological Interactions</i> , 2003, 143-144, 325-332.	4.0	21
10	Pathophysiological Consequences of KATP Channel Overactivity and Pharmacological Response to Glibenclamide in Skeletal Muscle of a Murine Model of Cantu ¹ Syndrome. <i>Frontiers in Pharmacology</i> , 2020, 11, 604885.	3.5	19
11	The Mechanism of High-Output Cardiac Hypertrophy Arising From Potassium Channel Gain-of-Function in Cantu Syndrome. <i>Function</i> , 2020, 1, zqaa004.	2.3	18
12	A Potential Role for Aldose Reductase in Steroid Metabolism. <i>Advances in Experimental Medicine and Biology</i> , 1996, 414, 465-473.	1.6	13
13	Complex consequences of Cantu syndrome SUR2 variant R1154Q in genetically modified mice. <i>JCI Insight</i> , 2021, 6, .	5.0	11
14	Consequences of SUR2[A478V] Mutation in Skeletal Muscle of Murine Model of Cantu Syndrome. <i>Cells</i> , 2021, 10, 1791.	4.1	10
15	Kinetic Alteration of Human Aldose Reductase by Mutagenesis of Cysteine Residues. <i>Advances in Experimental Medicine and Biology</i> , 1993, 328, 289-300.	1.6	4
16	Structure-Function Studies of FR-1. <i>Advances in Experimental Medicine and Biology</i> , 1999, , 435-443.	1.6	2
17	Aldo-Keto Reductases in the Stress Response of the Budding Yeast <i>Saccharomyces cerevisiae</i> . <i>ACS Symposium Series</i> , 2003, , 225-238.	0.5	0